Insider Trading activities of Melinta Therapeutics, Inc. /new/ (MLNT)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Melinta Therapeutics, Inc. /new/ (MLNT) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Melinta Therapeutics, Inc. /new/ since year 2005. Table 2 shows the detailed insider transactions of Melinta Therapeutics, Inc. /new/ since 2005. The reporting company's ticker symbol is MLNT. The reporting company's CIK number is 1461993.
The total value of stock buying since 2005 is $228,244,754.
The total value of stock sales since 2005 is $6,944,590.
The total value of stock option exercises since 2005 is $562,726.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Melinta Therapeutics, Inc. /new/ (MLNT).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-06 0 $0 13,000 $72,436 0 $0
2019-05 0 $0 0 $0 50,000 $0
2018-05 23,370,000 $116,855,450 0 $0 0 $0
2018-01 5,777,778 $78,000,003 0 $0 0 $0
2017-03 0 $0 150,000 $533,095 0 $0
2017-01 5,000 $14,720 1,043,060 $3,551,428 0 $0
2016-01 0 $0 842 $25,314 842 $0
2015-12 0 $0 10,000 $302,713 10,000 $22,799
2015-11 0 $0 12,200 $351,116 10,000 $22,799
2015-10 4,830 $86,231 0 $0 0 $0
2015-06 0 $0 50,000 $1,787,000 50,000 $0
2015-05 0 $0 9,000 $321,488 37,389 $284,268
2015-03 0 $0 0 $0 15,000 $196,500
2014-05 10,000 $90,980 0 $0 12,105 $17,310
2013-06 530,000 $3,710,000 0 $0 0 $0
2013-05 3,500 $30,100 0 $0 0 $0
2012-08 0 $0 0 $0 2,500 $19,050
2012-02 4,909,545 $29,457,270 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Melinta Therapeutics, Inc. /new/ insiders (MLNT)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-06-27 Johnson John (Chief Executive Officer) Sale 13,000 5.57 72,436
2019-05-22 Johnson John Option Ex 50,000 .00 0
2018-05-29 Duffy Erin (Chief Scientific Officer) Buy 4,000 5.00 20,000
2018-05-29 Cammarata Sue (Chief Medical Officer) Buy 4,000 5.00 20,000
2018-05-29 Estrem Paul (Chief Financial Officer) Buy 10,000 5.00 50,000
2018-05-29 Zaccardelli David (Director) Buy 40,000 5.00 200,000
2018-05-29 Wechsler Daniel Mark (See Remarks) Buy 50,000 5.00 250,000
2018-05-29 Ferro Kevin (Director) Buy 23,257,000 5.00 116,285,000
2018-05-25 Gill David N (Director) Buy 5,000 6.09 30,450
2018-01-05 Ferro Kevin (Director) Buy 5,777,778 13.50 78,000,003
2017-03-08 Goldstein Dov A Md Sale 99,900 3.57 356,443
2017-03-07 Goldstein Dov A Md Sale 50,100 3.53 176,652
2017-01-13 Goldstein Dov A Md Sale 105,460 3.40 358,564
2017-01-06 Goldstein Dov A Md Sale 437,600 3.64 1,592,864
2017-01-05 Goldstein Dov A Md Sale 500,000 3.20 1,600,000
2017-01-03 Gill David N (Director) Buy 5,000 2.94 14,720
2016-01-04 Goldstein Dov A Md Sale 842 30.07 25,314
2016-01-04 Goldstein Dov A Md Option Ex 842 .00 0
2015-12-15 Oldach David W. (Chief Medical Officer) Sale 1,778 30.00 53,340
2015-12-15 Oldach David W. (Chief Medical Officer) Option Ex 1,778 2.28 4,053
2015-12-11 Oldach David W. (Chief Medical Officer) Sale 8,222 30.33 249,373
2015-12-11 Oldach David W. (Chief Medical Officer) Option Ex 8,222 2.28 18,746
2015-11-09 Oldach David W. (Chief Medical Officer) Sale 12,200 28.78 351,116
2015-11-09 Oldach David W. (Chief Medical Officer) Option Ex 10,000 2.28 22,799
2015-10-26 Kong Garheng (Director) Buy 2,830 17.43 49,335
2015-10-26 Dougherty Michael R (Director) Buy 2,000 18.45 36,896
2015-06-22 Goldstein Dov A Md Sale 50,000 35.74 1,787,000
2015-06-22 Goldstein Dov A Md Option Ex 50,000 .00 0
2015-05-22 Fernandes Prabhavathi (President and CEO) Sale 9,000 35.72 321,488
2015-05-22 Fernandes Prabhavathi (President and CEO) Option Ex 37,389 7.60 284,268
2015-03-04 Kent Richard S (Director) Option Ex 15,000 13.10 196,500
2014-05-23 Johnson John (Director) Buy 10,000 9.10 90,980
2014-05-14 Fernandes Prabhavathi (President and CEO) Option Ex 12,105 1.43 17,310
2013-06-19 Quaker Bioventures Capital Ii, L.p. (10% Owner) Buy 265,000 7.00 1,855,000
2013-06-19 Neff P Sherrill (Director) Buy 265,000 7.00 1,855,000
2013-05-09 Fernandes Prabhavathi (President and CEO) Buy 3,500 8.60 30,100
2012-08-17 Morris I Wistar Iii (10% Owner) Option Ex 2,500 7.62 19,050
2012-02-08 Dougherty Dennis (10% Owner) Buy 1,221,648 6.00 7,329,888
2012-02-08 Neff P Sherrill (Director) Buy 1,189,805 6.00 7,138,830
2012-02-08 Morris I Wistar Iii (Director) Buy 70,766 6.00 424,596
2012-02-07 Elms Steve Buy 1,213,663 6.00 7,281,978
2012-02-07 Goldstein Dov A Md Buy 1,213,663 6.00 7,281,978

Insider trading activities including stock purchases, stock sales, and option exercises of MLNT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Melinta Therapeutics, Inc. /new/ (symbol MLNT, CIK number 1461993) see the Securities and Exchange Commission (SEC) website.




Real-time Insider Trading

Insider Officer Cluster Trading

Top Officer Buys of the Week

Top Officer Buys of the Month